ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements with these filters
Entero Healthcare clarified that Q4 FY26 profits were impacted by ₹11.40 Crore in one-off costs. Increased minority interest followed the acquisition of a 51.51% stake in Anand Chemiceutics.
Entero Healthcare Solutions filed its FY2026 Annual Secretarial Compliance Report. The report notes a ₹0.01 Crore BSE fine for a previous technical filing delay.
Entero Healthcare delivered on its FY26 guidance with 31.5% like-for-like revenue growth and 4% EBITDA margins. Management transitioned to organic growth and profitability, focusing on higher-margin MedTech segments.
Entero Healthcare subsidiary Sai Pharma will acquire Vishal Surgicals & Medicals for ₹2.91 Crore in cash. The acquisition strengthens the company's pharmaceutical and surgical distribution network.
Entero Healthcare's subsidiary is acquiring Vishal Surgicals for ₹6.30 Crore in cash. The acquisition strengthens the company's pharmaceutical and surgical distribution network by December 2026.
Entero Healthcare Solutions allotted 72,400 equity shares under its ESOP scheme. This routine issuance marginally increases the company's total paid-up share capital.
Entero Healthcare Solutions re-appointed three Independent Directors for five-year terms. These leadership continuities aim to maintain governance stability and provide long-term strategic oversight.
Entero delivered strong FY26 performance meeting all guidance parameters. Revenue grew 29.3% to ₹6,591 Cr with EBITDA margins expanding to 4.0%, driven by organic growth and 7 strategic acquisitions.
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,910 Cr (+42.6% YoY) and net profit of ₹45.1 Cr (+43.6% YoY) for Q4 FY26.
Entero Healthcare Solutions approved its FY26 audited financial results and several strategic re-appointments. The board also cleared the acquisition of Vishal Surgicals to expand operations.
Entero Healthcare Solutions scheduled a board meeting for May 25, 2026, to approve fiscal 2026 financial results. Trading window remains closed until 48 hours post-declaration.
Entero Healthcare Solutions Limited announced that the Regional Director has sanctioned the Scheme of Amalgamation of its wholly-owned subsidiaries, Chethana Pharma Distributors and CPD Pharma, with Rada Medisolutions. The consolidation aims to improve operational efficiencies and simplify the group structure. The scheme became effective from April 15, 2025.